about
Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virusResistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolismSynthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.Hepatitis C virus therapies: current treatments, targets and future perspectives.Molecular interaction studies of amorphous solid dispersions of the antimelanoma agent betulinic acidInitial therapy for human immunodeficiency virus: broadening the options.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro.Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems.Indolyl aryl sulphones as HIV-1 reverse transcriptase inhibitors: docking and 3D QSAR studies.Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro.Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli.Therapeutic applications of sulfamates
P2860
Q28084005-1E4CB813-92F7-40FA-AAEA-893005820300Q33842989-9231B25A-B494-47F8-9837-0683348E268BQ34123716-B77FBF6E-6965-4F3B-A12E-E26E411FEBD6Q34546376-F6164420-3016-4827-948B-88FC430E9878Q34674575-24E0CD97-30B9-41EE-9CA3-D154A0E44ABCQ35147050-700647EC-1581-47F0-9D72-6277FB2FB5F0Q35209956-B48058CA-6F59-4DBC-873F-E5D5759D5B82Q35759609-C9ACA822-26A0-4E6B-A219-52515CCBB5F2Q35917148-275A24DB-07A8-4B4A-A4C2-FAE01129815AQ36309602-8922D3BD-F2E3-4AF5-A45F-07DBA756A3B1Q36577317-5F3A515C-B5E9-40B8-85A7-9A091A6FB436Q36865898-6C3ACD27-8CB7-41CF-8042-2DC86074255AQ38089836-A5C5952D-2CC9-455E-82EE-B71BE2807456Q40797649-8997AA34-2D26-43AD-94EB-1EC1C5C6EBAEQ41813550-15BDE7E0-8FB1-4B5A-804C-9932589B8B85Q58863297-6C614797-4351-413A-851B-077801FBCEE3
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Highlights in the development of new antiviral agents.
@ast
Highlights in the development of new antiviral agents.
@en
type
label
Highlights in the development of new antiviral agents.
@ast
Highlights in the development of new antiviral agents.
@en
prefLabel
Highlights in the development of new antiviral agents.
@ast
Highlights in the development of new antiviral agents.
@en
P356
P1476
Highlights in the development of new antiviral agents.
@en
P2093
De Clercq E
P304
P356
10.2174/1389557024605474
P577
2002-04-01T00:00:00Z